enGene Announces Name Change to enGene Therapeutics Inc.
Business Wire (Tue, 7-Apr 8:00 AM ET)
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
Business Wire (Mon, 9-Mar 7:00 AM ET)
enGene to Participate in Upcoming Investor Conferences
Business Wire (Fri, 20-Feb 8:00 AM ET)
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Business Wire (Wed, 4-Feb 8:00 AM ET)
enGene’s $130 Million Offering Highlights Investor Confidence in Genetic Medicine Platform
Market Chameleon (Thu, 13-Nov 3:25 AM ET)
Market Chameleon (Tue, 11-Nov 5:28 AM ET)
Market Chameleon (Tue, 11-Nov 4:09 AM ET)
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Engene Therapeutics trades on the NASDAQ stock market under the symbol ENGN.
As of April 21, 2026, ENGN stock price declined to $8.51 with 171,743 million shares trading.
ENGN has a beta of 1.88, meaning it tends to be more sensitive to market movements. ENGN has a correlation of 0.08 to the broad based SPY ETF.
ENGN has a market cap of $570.04 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that ENGN belongs to (by Net Assets): AVSC, BBC.
ENGN has outperformed the market in the last year with a price return of +112.8% while the SPY ETF gained +35.2%. However, in the short term, ENGN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -6.5% vs +4.2% return in SPY. But in the last 2 weeks, ENGN shares have fared better than the market returning +17.5% compared to SPY +6.9%.
ENGN support price is $8.10 and resistance is $8.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENGN shares will trade within this expected range on the day.
